News and Announcements
Executive Director of Alcidion to Present at BioShares Biotech Summit
- Published July 26, 2016 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th July 2016, ASX Announcement
Alcidion Group Limited (ASX: ALC) is pleased to announce that Executive Director, Mr Nathan Buzza, will present a paper on “Opportunities for Investment in Digital Health” at the Bioshares Biotech Summit on July 29th 2016 in Queenstown, New Zealand.
A copy of the presentation, inclusive of presentation notes is included withthe announcement.
ABOUT ALCIDION GROUP
Alcidion is the brainchild of the former CEO of the SA Heath Department and Professor Malcolm Pradhan, a Stanford qualified physician. Over the past decade, Alcidion has invested $15m into the R&D of the cutting edge Clinical Decision Support System and is now focussed on commercializing the technology.
The introduction of Patient Protection & Affordable Care Act 2010 (“Obamacare”) requires US hospitals to accelerate the adoption of Electronic Medical Records. Alcidion is a leading supplier of these systems in Australia and is now seeking to expand its operations into the United States.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
